APA

Wu C., Xi C., Tong J., Zhao J., Jiang H., Wang J., Wang Y. & Liu H. (2019). Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia. : Acta pharmaceutica Sinica. B.

Chicago

Wu Chenglin, Xi Cong, Tong Junhua, Zhao Jing, Jiang Hualiang, Wang Jiang, Wang Yiping and Liu Hong. 2019. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia. : Acta pharmaceutica Sinica. B.

Harvard

Wu C., Xi C., Tong J., Zhao J., Jiang H., Wang J., Wang Y. and Liu H. (2019). Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia. : Acta pharmaceutica Sinica. B.

MLA

Wu Chenglin, Xi Cong, Tong Junhua, Zhao Jing, Jiang Hualiang, Wang Jiang, Wang Yiping and Liu Hong. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia. : Acta pharmaceutica Sinica. B. 2019.